117 related articles for article (PubMed ID: 38040341)
1. Hypoxia-activated glutamine antagonist prodrug combined with combretastatin A4 nanoparticles for tumor-selective metabolic blockade.
Zheng M; Xu H; Huang Y; Sun J; Zhang H; Lv Z; Liu Z; Tang Z; Chen X
J Control Release; 2024 Jan; 365():480-490. PubMed ID: 38040341
[TBL] [Abstract][Full Text] [Related]
2. A redox-responsive prodrug for tumor-targeted glutamine restriction.
Prange CJ; Sayed NYB; Feng B; Goepfert C; Trujillo DO; Hu X; Tang L
J Control Release; 2024 Apr; 368():251-264. PubMed ID: 38403173
[TBL] [Abstract][Full Text] [Related]
3. We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of
Lemberg KM; Vornov JJ; Rais R; Slusher BS
Mol Cancer Ther; 2018 Sep; 17(9):1824-1832. PubMed ID: 30181331
[TBL] [Abstract][Full Text] [Related]
4. Discovery of
Novotná K; Tenora L; Prchalová E; Paule J; Alt J; Veeravalli V; Lam J; Wu Y; Šnajdr I; Gori S; Mettu VS; Tsukamoto T; Majer P; Slusher BS; Rais R
J Med Chem; 2023 Nov; 66(22):15493-15510. PubMed ID: 37949450
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma.
Rais R; Jančařík A; Tenora L; Nedelcovych M; Alt J; Englert J; Rojas C; Le A; Elgogary A; Tan J; Monincová L; Pate K; Adams R; Ferraris D; Powell J; Majer P; Slusher BS
J Med Chem; 2016 Sep; 59(18):8621-33. PubMed ID: 27560860
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs.
Tenora L; Alt J; Dash RP; Gadiano AJ; Novotná K; Veeravalli V; Lam J; Kirkpatrick QR; Lemberg KM; Majer P; Rais R; Slusher BS
J Med Chem; 2019 Apr; 62(7):3524-3538. PubMed ID: 30892035
[TBL] [Abstract][Full Text] [Related]
7. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug.
Rais R; Lemberg KM; Tenora L; Arwood ML; Pal A; Alt J; Wu Y; Lam J; Aguilar JMH; Zhao L; Peters DE; Tallon C; Pandey R; Thomas AG; Dash RP; Seiwert T; Majer P; Leone RD; Powell JD; Slusher BS
Sci Adv; 2022 Nov; 8(46):eabq5925. PubMed ID: 36383674
[TBL] [Abstract][Full Text] [Related]
8. Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxia-Activated Prodrug Tirapazamine Therapy for Metastatic Tumors.
Yang S; Tang Z; Hu C; Zhang D; Shen N; Yu H; Chen X
Adv Mater; 2019 Mar; 31(11):e1805955. PubMed ID: 30680816
[TBL] [Abstract][Full Text] [Related]
9. Azide-Masked Resiquimod Activated by Hypoxia for Selective Tumor Therapy.
Sun J; Liu Z; Yao H; Zhang H; Zheng M; Shen N; Cheng J; Tang Z; Chen X
Adv Mater; 2023 Jul; 35(29):e2207733. PubMed ID: 37086177
[TBL] [Abstract][Full Text] [Related]
10. Model studies towards prodrugs of the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) containing a diazo precursor.
Gao RD; Hin N; Prchalová E; Pal A; Lam J; Rais R; Slusher BS; Tsukamoto T
Bioorg Med Chem Lett; 2021 Oct; 50():128321. PubMed ID: 34400301
[TBL] [Abstract][Full Text] [Related]
11. Novel Glutamine Antagonist JHU395 Suppresses MYC-Driven Medulloblastoma Growth and Induces Apoptosis.
Pham K; Maxwell MJ; Sweeney H; Alt J; Rais R; Eberhart CG; Slusher BS; Raabe EH
J Neuropathol Exp Neurol; 2021 Mar; 80(4):336-344. PubMed ID: 33712838
[TBL] [Abstract][Full Text] [Related]
12. Combretastatin A4 Nanodrug-Induced MMP9 Amplification Boosts Tumor-Selective Release of Doxorubicin Prodrug.
Jiang J; Shen N; Ci T; Tang Z; Gu Z; Li G; Chen X
Adv Mater; 2019 Nov; 31(44):e1904278. PubMed ID: 31549774
[TBL] [Abstract][Full Text] [Related]
13. Glutamine Antagonist JHU083 Normalizes Aberrant Glutamate Production and Cognitive Deficits in the EcoHIV Murine Model of HIV-Associated Neurocognitive Disorders.
Nedelcovych MT; Kim BH; Zhu X; Lovell LE; Manning AA; Kelschenbach J; Hadas E; Chao W; Prchalová E; Dash RP; Wu Y; Alt J; Thomas AG; Rais R; Kamiya A; Volsky DJ; Slusher BS
J Neuroimmune Pharmacol; 2019 Sep; 14(3):391-400. PubMed ID: 31209775
[TBL] [Abstract][Full Text] [Related]
14. Tumor-targeted metabolic inhibitor prodrug labelled with cyanine dyes enhances immunoprevention of lung cancer.
Li W; Huang J; Shen C; Jiang W; Yang X; Huang J; Gu Y; Li Z; Ma Y; Bian J
Acta Pharm Sin B; 2024 Feb; 14(2):751-764. PubMed ID: 38322332
[TBL] [Abstract][Full Text] [Related]
15. Combretastatin A4 Nanoparticles Combined with Hypoxia-Sensitive Imiquimod: A New Paradigm for the Modulation of Host Immunological Responses during Cancer Treatment.
Shen N; Wu J; Yang C; Yu H; Yang S; Li T; Chen J; Tang Z; Chen X
Nano Lett; 2019 Nov; 19(11):8021-8031. PubMed ID: 31558024
[TBL] [Abstract][Full Text] [Related]
16. NQO1-selective activated prodrugs of combretastatin A-4: Synthesis and biological evaluation.
Zhang C; Qu Y; Ma X; Li M; Li S; Li Y; Wu L
Bioorg Chem; 2020 Oct; 103():104200. PubMed ID: 32890998
[TBL] [Abstract][Full Text] [Related]
17. Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems.
Yokoyama Y; Estok TM; Wild R
Mol Cancer Ther; 2022 Oct; 21(10):1561-1572. PubMed ID: 35930753
[TBL] [Abstract][Full Text] [Related]
18. Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
Winn BA; Devkota L; Kuch B; MacDonough MT; Strecker TE; Wang Y; Shi Z; Gerberich JL; Mondal D; Ramirez AJ; Hamel E; Chaplin DJ; Davis P; Mason RP; Trawick ML; Pinney KG
J Nat Prod; 2020 Apr; 83(4):937-954. PubMed ID: 32196334
[TBL] [Abstract][Full Text] [Related]
19. Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine.
Wang SZ; Poore B; Alt J; Price A; Allen SJ; Hanaford AR; Kaur H; Orr BA; Slusher BS; Eberhart CG; Raabe EH; Rubens JA
Clin Cancer Res; 2019 Oct; 25(19):5925-5936. PubMed ID: 31300448
[TBL] [Abstract][Full Text] [Related]
20. Targeting glutamine metabolism exhibits anti-tumor effects in thyroid cancer.
Zhang GQ; Xi C; Ju NT; Shen CT; Qiu ZL; Song HJ; Luo QY
J Endocrinol Invest; 2024 Feb; ():. PubMed ID: 38386265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
